CN114126601B - α-酮戊二酸类化合物的持续释放组合物 - Google Patents

α-酮戊二酸类化合物的持续释放组合物

Info

Publication number
CN114126601B
CN114126601B CN202080052370.3A CN202080052370A CN114126601B CN 114126601 B CN114126601 B CN 114126601B CN 202080052370 A CN202080052370 A CN 202080052370A CN 114126601 B CN114126601 B CN 114126601B
Authority
CN
China
Prior art keywords
composition
ketoglutarate
calcium
alpha
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080052370.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114126601A (zh
Inventor
D·E·佩雷拉
S·科纳尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poncci Leon Health Specific Events
Original Assignee
Poncci Leon Health Specific Events
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poncci Leon Health Specific Events filed Critical Poncci Leon Health Specific Events
Publication of CN114126601A publication Critical patent/CN114126601A/zh
Application granted granted Critical
Publication of CN114126601B publication Critical patent/CN114126601B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN202080052370.3A 2019-06-10 2020-06-10 α-酮戊二酸类化合物的持续释放组合物 Active CN114126601B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962859595P 2019-06-10 2019-06-10
US62/859,595 2019-06-10
US201962929024P 2019-10-31 2019-10-31
US62/929,024 2019-10-31
PCT/US2020/036987 WO2020252014A1 (en) 2019-06-10 2020-06-10 Sustained-release compositions of alpha-ketoglutarate

Publications (2)

Publication Number Publication Date
CN114126601A CN114126601A (zh) 2022-03-01
CN114126601B true CN114126601B (zh) 2025-07-15

Family

ID=73781275

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080052370.3A Active CN114126601B (zh) 2019-06-10 2020-06-10 α-酮戊二酸类化合物的持续释放组合物

Country Status (11)

Country Link
US (1) US20220265586A1 (enExample)
EP (1) EP3980001B1 (enExample)
JP (2) JP7751291B2 (enExample)
KR (1) KR20220044478A (enExample)
CN (1) CN114126601B (enExample)
BR (1) BR112021024952A2 (enExample)
CA (1) CA3142494A1 (enExample)
DK (1) DK3980001T3 (enExample)
IL (1) IL288782A (enExample)
TW (1) TWI869410B (enExample)
WO (1) WO2020252014A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7499259B2 (ja) * 2018-09-25 2024-06-13 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
MX2024008182A (es) * 2021-12-29 2024-09-24 Jrs Pharma Gmbh & Co Kg Lubricante para productos farmacéuticos y nutracéuticos.
WO2024123738A1 (en) * 2022-12-06 2024-06-13 Ponce De Leon Health Designated Activity Company Compositions and methods for treating diseases responsive to akg-vitamin b coadministration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200736A2 (en) * 2017-04-25 2018-11-01 The Buck Institute For Research On Aging Formulations for extending lifespan and healthspan
CN110087632A (zh) * 2016-11-30 2019-08-02 麦提麦迪制药有限公司 乳酸钙组合物和使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
CN100400042C (zh) 1999-12-03 2008-07-09 聚合化学股份公司 制备生物利用度改善的麦角生物碱持续释放药物组合物的方法及其组合物
JP4169596B2 (ja) * 2000-12-20 2008-10-22 アルコン、インコーポレイテッド 白内障を液化破壊により取り除くための溶液
US20060029668A1 (en) 2002-10-24 2006-02-09 Ron Eyal S Sustained release L-arginine formulations and methods of manufacture and use
CA2574597A1 (en) * 2004-08-09 2006-02-16 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
FR2967578B1 (fr) 2010-11-18 2012-12-28 Advicenne Pharma Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
ITBO20120226A1 (it) * 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
MX377119B (es) * 2013-06-06 2025-03-07 Amip Llc Un sistema de dosis no alimenticia suministrable oralmente que comprende hierro y un agente.
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN108653221B (zh) * 2015-06-03 2021-09-07 南京三迭纪医药科技有限公司 药品剂型及其使用
EP3518915A4 (en) * 2016-09-30 2020-04-15 The Regents of the University of California ALPHA KETOBUTYRATE, ALPHA KETOGLUTARATE AND 2-HYDROXYBUTYRATE FOR STIMULATING HAIR GROWTH
MX2017004010A (es) * 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110087632A (zh) * 2016-11-30 2019-08-02 麦提麦迪制药有限公司 乳酸钙组合物和使用方法
WO2018200736A2 (en) * 2017-04-25 2018-11-01 The Buck Institute For Research On Aging Formulations for extending lifespan and healthspan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
α-酮戊二酸分离提取工艺的优化;杨雪晨，等;食品与发酵工业.;20221231;第48卷(第23期);第65-70页 *

Also Published As

Publication number Publication date
EP3980001B1 (en) 2025-08-27
CN114126601A (zh) 2022-03-01
JP2025124683A (ja) 2025-08-26
WO2020252014A1 (en) 2020-12-17
TWI869410B (zh) 2025-01-11
KR20220044478A (ko) 2022-04-08
EP3980001A4 (en) 2023-06-21
JP2022537685A (ja) 2022-08-29
US20220265586A1 (en) 2022-08-25
CA3142494A1 (en) 2020-12-17
EP3980001A1 (en) 2022-04-13
TW202112362A (zh) 2021-04-01
JP7751291B2 (ja) 2025-10-08
BR112021024952A2 (pt) 2022-02-15
IL288782A (en) 2022-02-01
DK3980001T3 (da) 2025-12-01
AU2020292278A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
AU2019268049B2 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
CN114126601B (zh) α-酮戊二酸类化合物的持续释放组合物
US9918975B2 (en) Method for improving dissolution of anticoagulant agent
CA2529746A1 (en) Oral extended-release composition
CN102036656A (zh) 含有蜡的缓释制剂
WO2007072908A1 (ja) 薬物含有ワックスマトリックス粒子の製造方法、該方法に使用されるエクストルーダー、及びシロスタゾールを含有する徐放性製剤
AU2011222856A1 (en) Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
US20110135723A1 (en) Pharmaceutical compositions containing pregabalin
TW201609195A (zh) 固體抗病毒劑型
MD3684344T2 (ro) Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
EP2726064A1 (en) Controlled release oral dosage form comprising oxycodone
AU2020292278B2 (en) Sustained-release compositions of alpha-ketoglutarate
HK40071632A (en) Sustained-release compositions of alpha-ketoglutarate
CN101006991A (zh) 小檗碱的缓释制剂
EP2543363A1 (en) Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
US20060083759A1 (en) Stabilization of the profile of release of active substances from a formulation
CN101011368A (zh) 曲克芦丁的缓释制剂
JP2021181483A (ja) 低１日用量で投与するためのフマル酸ジメチルを含む医薬組成物
EP2543361A1 (en) Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
EP3308773A1 (en) Formulations of cysteamine and cysteamine derivatives
CN101015535A (zh) 哌克昔林的缓释制剂
HK1121667B (en) Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
HK1180252B (en) Method for improving dissolvability of anticoagulant

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40071632

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant